7-methoxyquinoline-8-carboxylic acid | 1159427-80-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-methoxyquinoline-8-carboxylic acid
• 英文别名: 7-(Methyloxy)-8-quinolinecarboxylic acid
• CAS: 1159427-80-1
• 化学式: C₁₁H₉NO₃
• 分子量: 203.197
• InChiKey: YXDHBRKFWUOAPG-UHFFFAOYSA-N

物化性质

• 沸点：
  405.7±25.0 °C(Predicted)
• 密度：
  1.325±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-methoxyquinoline-8-carboxylic acid 在 氢溴酸 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 ethyl 7-ethoxyquinoline-8-carboxylate
  参考文献：
  名称：

  SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS

  摘要：

  本发明涉及式I的化合物：其中环A为苯基、萘基、吡啶基、喹啉基、异喹啉基、咪唑吡啉基、呋喃基、噻唑基、异噁唑基、吡唑基、咪唑噻唑基、苯并咪唑基或吲哚基；R1为H、烷基、烷氧基、羟基烷基、OH、卤素、苯基、三唑基、噁唑基、异噁唑基、吡啶基、嘧啶基、吡嗪基、吡啶并嗪基、哌嗪基、吡唑基、噁二唑基、吡咯烷基、噻吩基、吗啉基或二烷氨基；R2为H、烷基、烷氧基、羟基烷基或卤素；Z为NH、N-烷基或O；R5为吡啶基、嘧啶基、吡嗪基、吡啶并嗪基、喹唑啉基、喹喹啉基、吡唑基、苯并噁唑基、咪唑吡嗪基、三唑咪唑基，可选地取代一个或两个独立选择自烷基、烷氧基或卤素的基团；n为0或1，还描述了制备式I化合物的方法。本发明还涉及包含式I化合物的药物组合物。本发明还涉及使用该化合物的方法。

  公开号：

  US20160046640A1
• 作为产物：
  描述：

  2-氨基-6-甲氧基苯甲酸 、 丙烯醛 在 甲醇 、 二氯甲烷 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.33h， 以to afford the title compound (0.430 g, 35%) as a light orange solid的产率得到7-methoxyquinoline-8-carboxylic acid
  参考文献：
  名称：

  Prolyl Hydroxylase Inhibitors

  摘要：

  本发明涉及某些公式（I）的喹啉-8-羧酰胺衍生物，其为HIF脯氨酸羟化酶的拮抗剂，并且可用于治疗受益于抑制该酶的疾病，贫血是其中的一个例子。

  公开号：

  US20100305154A1

文献信息

• [EN] PROLYL HYDROXYLASE INHIBITORS<br/>[FR] INHIBITEURS DE PROLYL HYDROXYLASES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009070644A1

  公开（公告）日：2009-06-04

  The invention described herein relates to certain quinoline-8-carboxamide derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

  本发明涉及某些喹啉-8-羧酰胺衍生物（I）的拮抗剂，这些衍生物是HIF脯氨酸羟化酶的拮抗剂，并且适用于治疗受益于抑制该酶的疾病，贫血是一个例子。
• Substituted 7-azabicyles and their use as orexin receptor modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US09062078B2

  公开（公告）日：2015-06-23

  The present invention is directed to compounds of Formula I: wherein ring A is phenyl, naphthalenyl, pyridyl, quinolinyl, isoquinolinyl, imidazopyridyl, furanyl, thiazolyl, isoxazolyl, pyrazolyl, imidazothiazolyl, benzimidazolyl, or indazolyl; R1 is H, alkyl, alkoxy, hydroxyalkylene, OH, halo, phenyl, triazolyl, oxazolyl, isoxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, piperazinyl, pyrazolyl, oxadiazolyl, pyrrolidinyl, thiophenyl, morpholinyl, or dialkylamino; R2 is H, alkyl, alkoxy, hydroxyalkylene, or halo; Z is NH, N-alkyl, or O; R5 is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinazolinyl, quinoxalinyl, pyrazolyl, benzoxazolyl, imidazopyrazinyl, triazolopyrazinyl, optionally substituted with a one or two substituents independently selected from the group consisting of alkyl, alkoxy, or halo; and n is 0 or 1. Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.

  本发明涉及式I的化合物：其中环A是苯基，萘基，吡啶基，喹啉基，异喹啉基，咪唑吡啶基，呋喃基，噻唑基，异恶唑基，吡唑基，咪唑噻唑基，苯并咪唑基或吲唑基; R1是H，烷基，烷氧基，羟基烷基，OH，卤素，苯基，三唑基，噁唑基，异噁唑基，吡啶基，嘧啶基，吡嗪基，吡啶并嗪基，哌嗪基，吡唑基，噁二唑基，吡咯烷基，噻吩基，吗啉基或二烷基氨基; R2是H，烷基，烷氧基，羟基烷基或卤素; Z是NH，N-烷基或O; R5是吡啶基，嘧啶基，吡嗪基，吡啶并嗪基，喹唑啉基，喹喔啉基，吡唑基，苯并噁唑基，咪唑吡嗪基，三唑基咪唑基，可选地带有一个或两个烷基，烷氧基或卤素基团; n为0或1。还描述了制备式I化合物的方法。本发明还涉及包含式I化合物的制药组合物。使用本发明中的化合物的方法也属于本发明的范围。
• Substituted 2-azabicycles and their use as orexin receptor modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US08969352B2

  公开（公告）日：2015-03-03

  The present invention is directed to compounds of Formula I: wherein X is N or CR1; Y is N or CR2; R1 is H, alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl, isoxazole, oxadiazolyl, or pyrazolyl; R2 is H, alkyl, alkoxy, or halo; Z is NH or O; R3 is H, alkyl, alkoxy, halo, or triazolyl; R4 is H or alkyl; or R3 and R4, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring; R5 is pyridyl, pyrazinyl, or pyrimidinyl, wherein the pyridyl, pyrazinyl, or pyrimidinyl is optionally substituted with halo or alkyl; and n is 1 or 2. Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.

  本发明涉及式I的化合物：其中X为N或CR1; Y为N或CR2; R1为H、烷氧基、卤素、三唑基、嘧啶基、噁唑基、异噁唑基、噻二唑基或吡唑基; R2为H、烷基、烷氧基或卤素; Z为NH或O; R3为H、烷基、烷氧基、卤素或三唑基; R4为H或烷基; 或R3和R4与它们附着的原子一起形成6元芳基环或5-或6元杂芳基环; R5为吡啶基、吡嗪基或嘧啶基，其中吡啶基、吡嗪基或嘧啶基可以选择性地用卤素或烷基取代; n为1或2。还描述了制备式I化合物的方法。本发明还涉及包括式I化合物的制药组合物。使用本发明化合物的方法也在本发明的范围内。
• SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS
  申请人：Janssen Pharmaceutica NV

  公开号：US20150174129A1

  公开（公告）日：2015-06-25

  The present invention is directed to compounds of Formula I: wherein X is N or CR 1 ; Y is N or CR 2 ; R 1 is H, alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl, isoxazole, oxadiazolyl, or pyrazolyl; R 2 is H, alkyl, alkoxy, or halo; Z is NH or O; R 3 is H, alkyl, alkoxy, halo, or triazolyl; R 4 is H or alkyl; or R 3 and R 4 , together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring; R 5 is pyridyl, pyrazinyl, or pyrimidinyl, wherein the pyridyl, pyrazinyl, or pyrimidinyl is optionally substituted with halo or alkyl; and n is 1 or 2. Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.

  本发明涉及式I的化合物：其中X为N或CR1；Y为N或CR2；R1为H，烷氧基，卤素，三唑基，嘧啶基，噁唑基，异噁唑基，噻二唑基或吡唑基；R2为H，烷基，烷氧基或卤素；Z为NH或O；R3为H，烷基，烷氧基，卤素或三唑基；R4为H或烷基；或R3和R4与它们所连接的原子一起形成一个6元芳基环或5或6元杂芳基环；R5为吡啶基，吡嗪基或嘧啶基，其中吡啶基，吡嗪基或嘧啶基可以选择性地用卤素或烷基取代；n为1或2。本发明还描述了制备式I化合物的方法。本发明还涉及包含式I化合物的制药组合物。使用本发明中的化合物的方法也在本发明的范围内。
• SUBSTITUTED PIPERIDINE COMPOUNDS AND THEIR USE AS OREXIN RECEPTOR MODULATORS
  申请人：COATE Heather R.

  公开号：US20160046599A1

  公开（公告）日：2016-02-18

  The present invention is directed to compounds of Formula I: wherein X is CR 1 or N; Y is CR 2 or N; Z is NH or O; R 1 is alkoxy, triazolyl, oxazolyl, isoxazolyl, oxadiazolyl, or pyrimidinyl; R 2 is H, alkyl, or halo; R 3 is H, alkyl, alkoxy, halo, triazolyl, oxazolyl, or pyrimidinyl; R 4 is alkyl; R 5 is pyridyl; benzoxazolyl; pyrimidinyl; pyridazinyl; quinoxalinyl; pyrazinyl; or quinazolinyl; wherein the pyridyl; benzoxazolyl; pyrimidinyl; pyridazinyl; quinoxalinyl; pyrazinyl; or quinazolinyl is optionally substituted with one or two substituents independently selected from the group consisting of alkyl, halo, or phenyl; and R 6 is H or alkyl. Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods using the compounds of the invention are also within the scope of the invention.

  本发明涉及式I的化合物：其中X为CR1或N; Y为CR2或N; Z为NH或O; R1为烷氧基，三唑基，噁唑基，异噁唑基，噁二唑基或嘧啶基; R2为氢，烷基或卤素; R3为氢，烷基，烷氧基，卤素，三唑基，噁唑基或嘧啶基; R4为烷基; R5为吡啶基; 苯并噁唑基; 嘧啶基; 吡啶二氮杂苯基; 喹喔啉基; 吡嗪基; 或喹唑啉基; 其中吡啶基; 苯并噁唑基; 嘧啶基; 吡啶二氮杂苯基; 喹喔啉基; 吡嗪基; 或喹唑啉基可选地被一个或两个独立选择的取代基取代，所述取代基选自烷基，卤素或苯基; R6为氢或烷基。还描述了制备式I化合物的方法。本发明还涉及包含式I化合物的制药组合物。使用本发明中的化合物的方法也属于本发明的范围。